biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > RNAi

<< Previous

Bullboard Posts

Next >>

Comment by greaterfoolFredon May 03, 2023 11:49am

75 Views

Post# 35427666

RE:RE:RNAi

Boomskid wrote: I used to complain, ohhhh, about ten or twelve years ago, that if Bioasis didn't hurry up and do something that some other technology would come along and take a big bite out of Bioasis's cookie.

And yet, here we are, still noting every new thing that comes along that might take that bite, but nothing ever really has.

It's all still pretty much wide open.

If only...

jd

...if only XB3 could be shown to work in monkeys.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale